Search
Search Results
-
Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE
BackgroundSomatostatin receptors (SSTR) represent an ideal target for nuclear theranostics applications in neuroendocrine tumors (NET). Studies...
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
BackgroundHistorically, patient selection for peptide receptor radionuclide therapy (PRRT) has been performed by virtue of somatostatin receptor...
-
Post-PRRT scans: which scans to make and what to look for
AimThe aim of this study was to evaluate the clinical utility of SPECT/CT (imaging of uptake in tumor lesions and additional findings) and the...
-
Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients
PurposePeptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs)....
-
Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
BackgroundThe accumulation of 177 Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin...
-
The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry
PurposeMetastatic neuroendocrine tumors (NETs) overexpressing type 2 somatostatin receptors are the target for peptide receptor radionuclide therapy...
-
177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
PurposeGiven the recent and rapid development of peptide receptor radionuclide therapy (PRRT), increasing emphasis should be placed on the early...
-
Should peptide receptors radionuclide therapy (PRRT) be considered as a treatment of choice in functioning metastatic insulinomas? A review of literature and our center experience
PurposeThe aim of this study is to analyze peptide receptors radionuclide therapy (PRRT) effectiveness in functioning malignant insulinomas poorly...
-
-
Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study
BackgroundFollowing each cycle of peptide receptor radionuclide therapy (PRRT), absorbed doses by tumors and normal organs are typically calculated...
-
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
PurposeThe aim of this narrative review is to give an overview on current and emerging imaging methods and liquid biopsy for prediction and...
-
PRRT: identikit of the perfect patient
Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the...
-
Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations
BackgroundDosimetry promises many advantages for radiopharmaceutical therapies but repeat post-therapy imaging for dosimetry can burden both patients...
-
Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT)
Background/objectivesNeuroendocrine neoplasms (NEN) may predispose patients to malnutrition. CT-defined sarcopenia and myosteatosis are common in...
-
Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience
IntroductionThe available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from...
-
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival
PurposeTo determine prognostic factors and overall survival (OS) in therapy-related myeloid neoplasm (t-MN) of patients after receiving peptide...
-
-
Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report
BackgroundPeptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive...
